NCT02328781 (PESS) is a NA clinical trial of Drug-eluting stent in Vertebrobasilar Insufficiency, sponsored by Zhongrong Miao.

Who is sponsoring NCT02328781?

NCT02328781 is sponsored by Zhongrong Miao.

What drugs are being tested in NCT02328781?

Interventions in NCT02328781: Drug-eluting stent.

What condition does NCT02328781 study?

NCT02328781 studies Vertebrobasilar Insufficiency.

Is NCT02328781 still recruiting?

NCT02328781 is currently completed. Last updated 12 June 2020.

Last reviewed 2020-06-12 · How we verify

NCT02328781: PESS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System

Completed NA Last updated 12 June 2020

What this trial tests

NA trial testing Drug-eluting stent in Vertebrobasilar Insufficiency in 101 participants. Completed in 25 November 2016.

Timeline

17 July 2014

Primary endpoint
14 June 2016

25 November 2016

Quick facts

Lead sponsor	Zhongrong Miao
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	101
Start date	17 July 2014
Primary completion	14 June 2016
Estimated completion	25 November 2016
Sites	1 location across China

Drugs / interventions tested

Drug-eluting stent

Conditions studied

Vertebrobasilar Insufficiency — all drugs for Vertebrobasilar Insufficiency →

Sponsor

Zhongrong Miao

Who can join

Adults 18 to 80, any sex, with Vertebrobasilar Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of Firehorus vertebral artery rapamycin-target-eluting stent system (hereinafter referred to as Firehorus) in treatment of symptomatic vertebral artery stenosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Drug-eluting stent

Trials testing the same drug.

NCT07442500 — Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease · not yet recruiting
NCT06084000 — STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Les · NA · unknown
NCT05680051 — DCB Under the Guidance of OCT in STEMI · NA · unknown
NCT05493904 — PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX) · NA · active not recruiting
NCT05305482 — DCS Versus DES for One-month DAPT in Patients With ACS: ONE-PASS Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02328781 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhongrong Miao
Last refreshed: 12 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02328781.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing